Immix Biopharma, Inc.
Immix Biopharma, Inc. (Nasdaq: IMIX) is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor T-cell (CAR-T) therapies for serious diseases, with an emphasis on light chain (AL) amyloidosis and other conditions. The company's website is www.immixbiopharma.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Immix Biopharma, Inc. does
In the company’s own words
Immix Biopharma, Inc. (Nasdaq: IMIX) is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor T-cell (CAR-T) therapies for serious diseases, with an emphasis on light chain (AL) amyloidosis and other conditions. The company's website is www.immixbiopharma.com.
The company's lead candidate is NXC-201, a next-generation CAR-T therapy targeting B-cell maturation antigen (BCMA) currently being evaluated in the Phase 1b/2 NEXICART-2 clinical trial in the United States and the Phase 1b/2a NEXICART-1 trial outside the U.S. NXC-201 has received multiple regulatory designations including Regenerative Medicine Advanced Therapy (RMAT) designation, Orphan Drug Designation from both the FDA and European Commission, and Breakthrough Therapy designation from the FDA as of January 2026.
Immix's proprietary N-GENIUS platform consists of three key elements: a Purpose-Built Cell Therapy Evidence Capture Engine with relational database, proprietary EXPAND technology applied across multiple cell therapy indications, and an Atomized Novel Binding Scaffold Generation Engine. The platform has generated NXC-201, which features high transduction efficiency, low tonic signaling, and anti-exhaustion capability designed to minimize toxicity and enhance persistence.
AL amyloidosis is a life-threatening immunological disorder where abnormal proteins accumulate in tissues and organs, produced by long-lived plasma cells. The U.S. observed prevalence of relapsed/refractory AL amyloidosis is growing at twelve percent annually and is estimated to reach approximately 38,500 patients in 2026. As of March 2026, no FDA-approved drugs exist for relapsed/refractory AL amyloidosis. The global amyloidosis treatment market was valued at $5.80 billion in 2024 and is projected to reach $11.13 billion by 2033.
Recent clinical data from NEXICART-2 presented in December 2025 demonstrated a complete response rate of seventy-five percent in twenty patients treated with NXC-201. The company received an eight million dollar grant from the California Institute for Regenerative Medicine in July 2024 to support NXC-201's clinical development. Immix maintains a research and license agreement with Hadasit Medical Research Services and BIRAD for exclusive worldwide rights to anti-BCMA CAR-T technology outside Israel and the Middle East.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- LOS ANGELES, CA
- Fiscal year end
- December
- CIK
- 1873835
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Immix Biopharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Immix Biopharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Immix Biopharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Immix Biopharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Immix Biopharma, Inc.'s last four quarterly filings that the numbers alone won't show?”